Evidence map›Paper›PMID 38474377›Full record

ReviewCells2024

The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC).

Che-Wei Wang, Pulak Kumar Biswas, Atikul Islam, Mu-Kuan Chen, Pin Ju Chueh

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 30 citations in OpenAlex.

  1. Head and neck squamous cell carcinoma: current and emerging therapeutic strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Che-Wei WangInstitute of Biomedical Sciences, National Chung Hsing University, Taichung 40227, Taiwan.
Pulak Kumar BiswasInstitute of Molecular Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
Atikul IslamInstitute of Biomedical Sciences, National Chung Hsing University, Taichung 40227, Taiwan.
Mu-Kuan ChenDepartment of Otorhinolaryngology-Head and Neck Surgery, Changhua Christian Hospital, Changhua 50006, Taiwan.
Pin Ju ChuehInstitute of Biomedical Sciences, National Chung Hsing University, Taichung 40227, Taiwan.ORCID 0000-0002-3200-7552
National Chung Hsing University · TWChanghua Christian Hospital · TWNational Cheng Kung University · TW

Funding

National Chung Hsing University and Changhua Christian Hospital NCHU-CCH 11105
6 · The paper itself

Abstract

Immunotherapy has emerged as a promising new treatment modality for head and neck cancer, offering the potential for targeted and effective cancer management. Squamous cell carcinomas pose significant challenges due to their aggressive nature and limited treatment options. Conventional therapies such as surgery, radiation, and chemotherapy often have limited success rates and can have significant side effects. Immunotherapy harnesses the power of the immune system to recognize and eliminate cancer cells, and thus represents a novel approach with the potential to improve patient outcomes. In the management of head and neck squamous cell carcinoma (HNSCC), important contributions are made by immunotherapies, including adaptive cell therapy (ACT) and immune checkpoint inhibitor therapy. In this review, we are focusing on the latter. Immune checkpoint inhibitors target proteins such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to enhance the immune response against cancer cells. The CTLA-4 inhibitors, such as ipilimumab and tremelimumab, have been approved for early-stage clinical trials and have shown promising outcomes in terms of tumor regression and durable responses in patients with advanced HNSCC. Thus, immune checkpoint inhibitor therapy holds promise in overcoming the limitations of conventional therapies. However, further research is needed to optimize treatment regimens, identify predictive biomarkers, and overcome potential resistance mechanisms. With ongoing advancements in immunotherapy, the future holds great potential for transforming the landscape of oral tumor treatment and providing new hope for patients.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapySquamous Cell Carcinoma of Head and NeckImmune Checkpoint Inhibitorscombination therapycytotoxic T-lymphocyte-associated protein 4 (CTLA-4)head and neck squamous cell carcinoma (HNSCC)immune checkpoint inhibitorsimmunotherapyoral carcinomaprogrammed cell death protein 1programmed death ligand-1 (PD-1/PD-L1)tumor microenvironment

Identifiers

PMID38474377
PMCPMC10930979
OpenAlexW4392198072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.